Liposomal Nano-pharmaceuticals

  • Improved therapeutic index (increased efficacy & reduced toxicity) by:
    • Passive targeted accumulation in diseased tissue
    • Sparing healthy tissues / organs
  • Protect API allowing controlled/sustained release at target
  • Biocompatible, biodegradable, non immunogenic
  • Scientifically well accepted nano delivery system
  • FDA is increasingly accustomed to Liposomal drugs – growth in the submissions of drug products containing nanomaterials, largest class of products being Liposomal formulations intended for cancer treatments*
  • Provides high entrance barriers for competition
  • Liposomal nano technology is advantageous in many indications (e.g. cancer, inflammation, infection)

Ayana has core competence in development & manufacturing of complex Liposomal nano-drugs

* Nature Nanotechnology Analysis (published on-line April 17, 2017)

error: Content is protected !!